financetom
Business
financetom
/
Business
/
illumin Announced TSX Acceptance of Normal Course Issuer Bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
illumin Announced TSX Acceptance of Normal Course Issuer Bid
Dec 19, 2024 6:45 AM

09:19 AM EST, 12/19/2024 (MT Newswires) -- illumin Holdings Inc. ( ILLMF ) on Thursday announced that it has received approval from the Toronto Stock Exchange to proceed with a normal course issuer bid.

Under the NCIB, the company may purchase for cancellation up to 3,914,167 common shares of the company. As at December 10, 2024, illumin had 50,954,061 shares issued and outstanding. As such, the maximum number of shares that may be purchased under the NCIB represents approximately 10% of illumin's public float as at December 10, 2024, being 3,914,167 shares.

In connection with the NCIB, illumin has entered into an automatic share purchase plan.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Msc Industrial Direct Insider Sold Shares Worth $413,251, According to a Recent SEC Filing
Msc Industrial Direct Insider Sold Shares Worth $413,251, According to a Recent SEC Filing
Jul 18, 2024
10:51 AM EDT, 07/18/2024 (MT Newswires) -- Kimberly Shacklett, Senior Vice President, Sales & Customer Success, on July 17, 2024, sold 4,885 shares in Msc Industrial Direct ( MSM ) for $413,251. Following the Form 4 filing with the SEC, Shacklett has control over a total of 12,897 shares of the company, with 12,897 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1003078/000100307824000078/xslF345X03/wk-form4_1721313759.xml...
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Jul 18, 2024
10:54 AM EDT, 07/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it completed enrollment in a clinical trial of zilganersen, an investigational ribonucleic acid-targeted medicine to treat children and adults with Alexander disease, a neurological disorder. Topline data are expected in H2 2025. The study is the first trial to evaluate an investigational medicine designed to address...
What's Going On With Amazon On Thursday?
What's Going On With Amazon On Thursday?
Jul 18, 2024
Amazon.com Inc ( AMZN ) on Thursday announced record-breaking sales for its 2024 Prime Day event. What Happened: Amazon ( AMZN ) said it sold more items during this year’s two-day Prime Day event than it did in any prior years, resulting in record Prime Day sales for the e-commerce giant. Amazon ( AMZN ) noted that a record-breaking number...
General Mills Appoints Chief Strategy & Growth Officer
General Mills Appoints Chief Strategy & Growth Officer
Jul 18, 2024
10:53 AM EDT, 07/18/2024 (MT Newswires) -- General Mills ( GIS ) said Thursday it has appointed Asheesh Saksena as chief strategy & growth officer, effective Aug. 26. Saksena succeeds Dana McNabb, following her prior appointment to group president, North America Retail, the firm said. He most recently served as chief growth officer for Gap (GPS). Price: 66.15, Change: +0.81,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved